6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
discussed O
in O
greater O
detail O
in O
other O
sections O
of O
the O
labeling O
: O
* O
Hepatotoxicity B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Interstitial B-OSE_Labeled_AE
Lung I-OSE_Labeled_AE
Disease I-OSE_Labeled_AE
( O
Pneumonitis O
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
QT B-OSE_Labeled_AE
Interval I-OSE_Labeled_AE
Prolongation I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Bradycardia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Severe O
Visual B-OSE_Labeled_AE
Loss I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
EXCERPT O
: O
The O
most O
common O
adverse O
reactions O
( O
> O
=25 O
% O
) O
are O
vision O
disorders O
, O
nausea O
, O
diarrhea O
, O
vomiting O
, O
edema O
, O
constipation O
, O
elevated O
transaminases O
, O
fatigue O
, O
decreased O
appetite O
, O
upper O
respiratory O
infection O
, O
dizziness O
, O
and O
neuropathy O
. O

( O
6 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Pfizer O
Inc O
. O
at O
1-800-438-1985 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

The O
data O
in O
the O
Warnings O
and O
Precautions O
section O
reflect O
exposure O
to O
XALKORI O
in O
1719 O
patients O
who O
received O
XALKORI O
250 O
mg O
twice O
daily O
enrolled O
on O
Studies O
1 O
( O
including O
an O
additional O
109 O
patients O
who O
crossed O
over O
from O
the O
control O
arm O
) O
, O
2 O
, O
3 O
, O
a O
single O
arm O
trial O
( O
n=1063 O
) O
of O
ALK B-Not_AE_Candidate
- I-Not_AE_Candidate
positive I-Not_AE_Candidate
NSCLC B-Not_AE_Candidate
, O
and O
an O
additional O
ALK B-Not_AE_Candidate
- I-Not_AE_Candidate
positive I-Not_AE_Candidate
NSCLC B-Not_AE_Candidate
expansion O
cohort O
of O
a O
dose O
finding O
study O
( O
n=154 O
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5 O
) O
] O
. O

The O
data O
described O
below O
is O
based O
primarily O
on O
343 O
patients O
with O
ALK B-Not_AE_Candidate
- I-Not_AE_Candidate
positive I-Not_AE_Candidate
metastatic B-Not_AE_Candidate
NSCLC I-Not_AE_Candidate
who O
received O
XALKORI O
250 O
mg O
twice O
daily O
from O
2 O
open-label O
, O
randomized O
, O
active-controlled O
trials O
( O
Studies O
1 O
and O
2 O
) O
. O

The O
safety O
of O
XALKORI O
was O
also O
evaluated O
in O
50 O
patients O
with O
ROS1-positive O
metastatic B-Not_AE_Candidate
NSCLC I-Not_AE_Candidate
from O
a O
single-arm O
study O
( O
Study O
3 O
) O
. O

The O
most O
common O
adverse O
reactions O
( O
> O
=25 O
% O
) O
of O
XALKORI O
are O
vision B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
edema B-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
elevated B-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
and O
neuropathy B-OSE_Labeled_AE
. O

Previously O
Untreated O
ALK-Positive O
Metastatic O
NSCLC O
- O
Study O
1 O
The O
data O
in O
Table O
3 O
are O
derived O
from O
340 O
patients O
with O
ALK B-Not_AE_Candidate
- I-Not_AE_Candidate
positive I-Not_AE_Candidate
metastatic O
NSCLC B-Not_AE_Candidate
who O
had O
not O
received O
previous O
systemic O
treatment O
for O
advanced O
disease O
who O
received O
treatment O
in O
a O
randomized O
, O
multicenter O
, O
open-label O
, O
active-controlled O
trial O
( O
Study O
1 O
) O
. O

Patients O
in O
the O
XALKORI O
arm O
( O
n=171 O
) O
received O
XALKORI O
250 O
mg O
orally O
twice O
daily O
until O
documented O
disease O
progression O
, O
intolerance O
to O
therapy O
, O
or O
the O
investigator O
determined O
that O
the O
patient O
was O
no O
longer O
experiencing O
clinical O
benefit O
. O

A O
total O
of O
169 O
patients O
in O
the O
chemotherapy O
arm O
received O
pemetrexed O
500 O
mg/m O
2 O
in O
combination O
with O
cisplatin O
75 O
mg/m O
2 O
( O
n=91 O
) O
or O
carboplatin O
at O
a O
dose O
calculated O
to O
produce O
an O
area O
under O
the O
concentration-time O
curve O
( O
AUC O
) O
of O
5 O
or O
6 O
mg O
min/mL O
( O
n=78 O
) O
. O

Chemotherapy O
was O
given O
by O
intravenous O
infusion O
every O
3 O
weeks O
for O
up O
to O
6 O
cycles O
, O
in O
the O
absence O
of O
dose-limiting O
chemotherapy-related O
toxicities O
. O

After O
6 O
cycles O
, O
patients O
remained O
on O
study O
with O
no O
additional O
anticancer O
treatment O
, O
and O
tumor O
assessments O
continued O
until O
documented O
disease O
progression O
. O

The O
median O
duration O
of O
study O
treatment O
was O
10.9 O
months O
for O
patients O
in O
the O
XALKORI O
arm O
and O
4.1 O
months O
for O
patients O
in O
the O
chemotherapy O
arm O
. O

Median O
duration O
of O
treatment O
was O
5.2 O
months O
for O
patients O
who O
received O
XALKORI O
after O
cross O
over O
from O
chemotherapy O
. O

Across O
the O
340 O
patients O
who O
were O
treated O
in O
Study O
1 O
, O
the O
median O
age O
was O
53 O
years O
; O
16 O
% O
of O
patients O
were O
older O
than O
65 O
years O
. O

A O
total O
of O
62 O
% O
of O
patients O
were O
female O
and O
46 O
% O
were O
Asian O
. O

Serious O
adverse O
events O
were O
reported O
in O
58 O
patients O
( O
34 O
% O
) O
treated O
with O
XALKORI O
. O

The O
most O
frequent O
serious O
adverse O
events O
reported O
in O
patients O
treated O
with O
XALKORI O
were O
dyspnea B-OSE_Labeled_AE
( O
4.1 O
% O
) O
and O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
( O
2.9 O
% O
) O
. O

Fatal O
adverse O
events O
in O
XALKORI-treated O
patients O
occurred O
in O
2.3 O
% O
patients O
, O
consisting O
of O
septic B-OSE_Labeled_AE
shock I-OSE_Labeled_AE
, O
acute B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
and O
diabetic B-OSE_Labeled_AE
ketoacidosis I-OSE_Labeled_AE
. O

Dose O
reductions O
due O
to O
adverse O
reactions O
were O
required O
in O
6.4 O
% O
of O
XALKORI-treated O
patients O
. O

The O
most O
frequent O
adverse O
reactions O
that O
led O
to O
dose O
reduction O
in O
these O
patients O
were O
nausea B-OSE_Labeled_AE
( O
1.8 O
% O
) O
and O
elevated B-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
( O
1.8 O
% O
) O
. O

Permanent O
discontinuation O
of O
XALKORI O
treatment O
for O
adverse O
reactions O
was O
8.2 O
% O
. O

The O
most O
frequent O
adverse O
reactions O
that O
led O
to O
permanent O
discontinuation O
in O
XALKORI-treated O
patients O
were O
elevated B-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
( O
1.2 O
% O
) O
, O
hepatotoxicity B-OSE_Labeled_AE
( O
1.2 O
% O
) O
, O
and O
ILD B-OSE_Labeled_AE
( O
1.2 O
% O
) O
. O

Tables O
3 O
and O
4 O
summarize O
common O
adverse O
reactions O
and O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
in O
XALKORI-treated O
patients O
. O

Table O
3 O
. O

Adverse O
Reactions O
Reported O
at O
a O
Higher O
Incidence O
( O
> O
=5 O
% O
Higher O
for O
All O
Grades O
or O
> O
=2 O
% O
Higher O
for O
Grades O
3-4 O
) O
with O
XALKORI O
than O
Chemotherapy O
in O
Study O
1Adverse O
reactions O
were O
graded O
using O
NCI O
CTCAE O
version O
4.0.Includes O
cases O
reported O
within O
the O
clustered O
terms O
: O
Adverse O
Reaction O
XALKORI O
( O
N=171 O
) O
Chemotherapy O
( O
Pemetrexed/Cisplatin O
or O
Pemetrexed/Carboplatin O
) O
( O
N=169 O
) O
All O
Grades O
( O
% O
) O
Grade O
3-4 O
( O
% O
) O
All O
Grades O
( O
% O
) O
Grade O
3-4 O
( O
% O
) O
Cardiac B-NonOSE_AE
Disorders I-NonOSE_AE
Electrocardiogram B-OSE_Labeled_AE
QT I-OSE_Labeled_AE
prolonged I-OSE_Labeled_AE
6 O
2 O
2 O
0 O
Bradycardia B-OSE_Labeled_AE
[ O
note O
: O
Bradycardia B-OSE_Labeled_AE
( O
Bradycardia B-OSE_Labeled_AE
, O
Sinus B-OSE_Labeled_AE
bradycardia I-OSE_Labeled_AE
) O
. O
] O

14 O
1 O
1 O
0 O
Eye B-NonOSE_AE
Disorders I-NonOSE_AE
Vision B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
[ O
note O
: O
Vision B-OSE_Labeled_AE
Disorder I-OSE_Labeled_AE
( O
Diplopia B-OSE_Labeled_AE
, O
Photophobia B-OSE_Labeled_AE
, O
Photopsia B-OSE_Labeled_AE
, O
Reduced B-OSE_Labeled_AE
visual I-OSE_Labeled_AE
acuity I-OSE_Labeled_AE
, O
Blurred B-OSE_Labeled_AE
vision I-OSE_Labeled_AE
, O
Vitreous B-OSE_Labeled_AE
floaters I-OSE_Labeled_AE
, O
Visual B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
) O
. O
] O

71 O
1 O
10 O
0 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Vomiting B-OSE_Labeled_AE
46 O
2 O
36 O
3 O
Diarrhea B-OSE_Labeled_AE
61 O
2 O
13 O
1 O
Constipation B-OSE_Labeled_AE
43 O
2 O
30 O
0 O
Dyspepsia B-OSE_Labeled_AE
14 O
0 O
2 O
0 O
Dysphagia B-OSE_Labeled_AE
10 O
1 O
2 O
1 O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
[ O
note O
: O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
Abdominal B-OSE_Labeled_AE
discomfort I-OSE_Labeled_AE
, O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
Lower B-OSE_Labeled_AE
abdominal I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
Upper B-OSE_Labeled_AE
abdominal I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
Abdominal B-OSE_Labeled_AE
tenderness I-OSE_Labeled_AE
) O
. O
] O

26 O
0 O
12 O
0 O
Esophagitis B-OSE_Labeled_AE
[ O
note O
: O
Esophagitis B-OSE_Labeled_AE
( O
Esophagitis B-OSE_Labeled_AE
, O
Esophageal B-OSE_Labeled_AE
ulcer I-OSE_Labeled_AE
) O
. O
] O

6 O
2 O
1 O
0 O
General B-NonOSE_AE
Disorders I-NonOSE_AE
and I-NonOSE_AE
Administration I-NonOSE_AE
Site I-NonOSE_AE
Conditions I-NonOSE_AE
Edema B-OSE_Labeled_AE
[ O
note O
: O
Edema B-OSE_Labeled_AE
( O
Edema B-OSE_Labeled_AE
, O
Peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
Face B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
Generalized B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
Local B-OSE_Labeled_AE
swelling I-OSE_Labeled_AE
, O
Periorbital B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
) O
. O
] O

49 O
1 O
12 O
1 O
Pyrexia B-OSE_Labeled_AE
19 O
0 O
11 O
1 O
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
[ O
note O
: O
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
Nasopharyngitis B-OSE_Labeled_AE
, O
Pharyngitis B-OSE_Labeled_AE
, O
Rhinitis B-OSE_Labeled_AE
, O
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
) O
. O
] O

32 O
0 O
12 O
1 O
Investigations B-NonOSE_AE
Increased B-OSE_Labeled_AE
weight I-OSE_Labeled_AE
8 O
1 O
2 O
0 O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
Connective I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
16 O
0 O
7 O
0 O
Muscle B-OSE_Labeled_AE
spasm I-OSE_Labeled_AE
8 O
0 O
2 O
1 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Dizziness B-OSE_Labeled_AE
[ O
note O
: O
Dizziness B-OSE_Labeled_AE
( O
Balance B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
Dizziness B-OSE_Labeled_AE
, O
Postural B-OSE_Labeled_AE
dizziness I-OSE_Labeled_AE
, O
Presyncope B-OSE_Labeled_AE
) O
. O
] O

18 O
0 O
10 O
1 O
Dysgeusia B-OSE_Labeled_AE
26 O
0 O
5 O
0 O
Headache B-OSE_Labeled_AE
22 O
1 O
15 O
0 O
Additional O
adverse O
reactions O
occurring O
at O
an O
overall O
incidence O
between O
1 O
% O
and O
60 O
% O
in O
patients O
treated O
with O
XALKORI O
included O
nausea B-OSE_Labeled_AE
( O
56 O
% O
) O
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
( O
30 O
% O
) O
, O
fatigue B-OSE_Labeled_AE
( O
29 O
% O
) O
, O
neuropathy B-OSE_Labeled_AE
( O
21 O
% O
; O
gait B-OSE_Labeled_AE
disturbance I-OSE_Labeled_AE
, O
hypoesthesia B-OSE_Labeled_AE
, O
muscular B-OSE_Labeled_AE
weakness I-OSE_Labeled_AE
, O
neuralgia B-OSE_Labeled_AE
, O
neuropathy B-OSE_Labeled_AE
peripheral I-OSE_Labeled_AE
, O
paresthesia B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
sensory I-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
, O
polyneuropathy B-OSE_Labeled_AE
, O
sensory B-OSE_Labeled_AE
disturbance I-OSE_Labeled_AE
) O
, O
rash B-OSE_Labeled_AE
( O
11 O
% O
) O
, O
renal B-OSE_Labeled_AE
cyst I-OSE_Labeled_AE
( O
5 O
% O
) O
, O
ILD B-OSE_Labeled_AE
( O
1 O
% O
; O
ILD B-OSE_Labeled_AE
, O
pneumonitis B-OSE_Labeled_AE
) O
, O
syncope B-OSE_Labeled_AE
( O
1 O
% O
) O
, O
and O
decreased B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
testosterone I-OSE_Labeled_AE
( O
1 O
% O
; O
hypogonadism B-OSE_Labeled_AE
) O
. O

Table O
4 O
. O

Laboratory O
Abnormalities O
with O
Grade O
3 O
or O
4 O
Incidence O
of O
> O
=4 O
% O
in O
XALKORI-Treated O
Patients O
in O
Study O
1 O
Laboratory O
Abnormality O
XALKORI O
Chemotherapy O
Any O
Grade O
( O
% O
) O
Grade O
3-4 O
( O
% O
) O
Any O
Grade O
( O
% O
) O
Grade O
3-4 O
( O
% O
) O
Additional O
laboratory B-NonOSE_AE
test I-NonOSE_AE
abnormality I-NonOSE_AE
in O
patients O
treated O
with O
XALKORI O
was O
an O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
( O
Any O
Grade O
: O
99 O
% O
; O
Grade O
3 O
: O
2 O
% O
; O
Grade O
4 O
: O
0 O
% O
) O
compared O
to O
the O
chemotherapy O
arm O
( O
Any O
Grade O
: O
92 O
% O
; O
Grade O
3 O
: O
0 O
% O
; O
Grade O
4 O
: O
1 O
% O
) O
. O

Hematology B-NonOSE_AE
Neutropenia B-OSE_Labeled_AE
52 O
11 O
59 O
16 O
Lymphopenia B-OSE_Labeled_AE
48 O
7 O
53 O
13 O
Chemistry B-NonOSE_AE
ALT B-OSE_Labeled_AE
elevation I-OSE_Labeled_AE
79 O
15 O
33 O
2 O
AST B-OSE_Labeled_AE
elevation I-OSE_Labeled_AE
66 O
8 O
28 O
1 O
Hypophosphatemia B-OSE_Labeled_AE
32 O
10 O
21 O
6 O
Previously O
Treated O
ALK-Positive O
Metastatic O
NSCLC O
- O
Study O
2 O
The O
data O
in O
Table O
5 O
are O
derived O
from O
343 O
patients O
with O
ALK B-Not_AE_Candidate
- I-Not_AE_Candidate
positive I-Not_AE_Candidate
metastatic B-Not_AE_Candidate
NSCLC I-Not_AE_Candidate
enrolled O
in O
a O
randomized O
, O
multicenter O
, O
active-controlled O
, O
open-label O
trial O
( O
Study O
2 O
) O
. O

Patients O
in O
the O
XALKORI O
arm O
( O
n=172 O
) O
received O
XALKORI O
250 O
mg O
orally O
twice O
daily O
until O
documented O
disease O
progression O
, O
intolerance O
to O
therapy O
, O
or O
the O
investigator O
determined O
that O
the O
patient O
was O
no O
longer O
experiencing O
clinical O
benefit O
. O

A O
total O
of O
171 O
patients O
in O
the O
chemotherapy O
arm O
received O
pemetrexed O
500 O
mg/m O
2 O
( O
n=99 O
) O
or O
docetaxel O
75 O
mg/m O
2 O
( O
n=72 O
) O
by O
intravenous O
infusion O
every O
3 O
weeks O
until O
documented O
disease O
progression O
, O
intolerance O
to O
therapy O
, O
or O
the O
investigator O
determined O
that O
the O
patient O
was O
no O
longer O
experiencing O
clinical O
benefit O
. O

Patients O
in O
the O
chemotherapy O
arm O
received O
pemetrexed O
unless O
they O
had O
received O
pemetrexed O
as O
part O
of O
first-line O
or O
maintenance O
treatment O
. O

The O
median O
duration O
of O
study O
treatment O
was O
7.1 O
months O
for O
patients O
who O
received O
XALKORI O
and O
2.8 O
months O
for O
patients O
who O
received O
chemotherapy O
. O

Across O
the O
347 O
patients O
who O
were O
randomized O
to O
study O
treatment O
( O
343 O
received O
at O
least O
1 O
dose O
of O
study O
treatment O
) O
, O
the O
median O
age O
was O
50 O
years O
; O
14 O
% O
of O
patients O
were O
older O
than O
65 O
years O
. O

A O
total O
of O
56 O
% O
of O
patients O
were O
female O
and O
45 O
% O
of O
patients O
were O
Asian O
. O

Serious O
adverse O
reactions O
were O
reported O
in O
64 O
patients O
( O
37.2 O
% O
) O
treated O
with O
XALKORI O
and O
40 O
patients O
( O
23.4 O
% O
) O
in O
the O
chemotherapy O
arm O
. O

The O
most O
frequent O
serious O
adverse O
reactions O
reported O
in O
patients O
treated O
with O
XALKORI O
were O
pneumonia B-OSE_Labeled_AE
( O
4.1 O
% O
) O
, O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
( O
3.5 O
% O
) O
, O
dyspnea B-OSE_Labeled_AE
( O
2.3 O
% O
) O
, O
and O
ILD B-OSE_Labeled_AE
( O
2.9 O
% O
) O
. O

Fatal B-NonOSE_AE
adverse O
reactions O
in O
XALKORI-treated O
patients O
in O
Study O
2 O
occurred O
in O
9 O
( O
5 O
% O
) O
patients O
, O
consisting O
of O
: O
acute B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
distress I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
arrhythmia B-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
pneumonia B-OSE_Labeled_AE
, O
pneumonitis B-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
, O
ILD B-OSE_Labeled_AE
, O
respiratory B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
and O
sepsis B-OSE_Labeled_AE
. O

Dose O
reductions O
due O
to O
adverse O
reactions O
were O
required O
in O
16 O
% O
of O
XALKORI-treated O
patients O
. O

The O
most O
frequent O
adverse O
reactions O
that O
led O
to O
dose O
reduction O
in O
the O
patients O
treated O
with O
XALKORI O
were O
ALT B-OSE_Labeled_AE
elevation I-OSE_Labeled_AE
( O
7.6 O
% O
) O
including O
some O
patients O
with O
concurrent O
AST B-OSE_Labeled_AE
elevation I-OSE_Labeled_AE
, O
QTc B-OSE_Labeled_AE
prolongation I-OSE_Labeled_AE
( O
2.9 O
% O
) O
, O
and O
neutropenia B-OSE_Labeled_AE
( O
2.3 O
% O
) O
. O

XALKORI O
was O
discontinued O
for O
adverse O
reactions O
in O
15 O
% O
of O
patients O
. O

The O
most O
frequent O
adverse O
reactions O
that O
led O
to O
discontinuation O
of O
XALKORI O
were O
ILD B-OSE_Labeled_AE
( O
1.7 O
% O
) O
, O
ALT B-OSE_Labeled_AE
and O
AST O
elevation I-OSE_Labeled_AE
( O
1.2 O
% O
) O
, O
dyspnea B-OSE_Labeled_AE
( O
1.2 O
% O
) O
, O
and O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
( O
1.2 O
% O
) O
. O

Tables O
5 O
and O
6 O
summarize O
common O
adverse O
reactions O
and O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
in O
XALKORI-treated O
patients O
. O

Table O
5 O
. O

Adverse O
Reactions O
Reported O
at O
a O
Higher O
Incidence O
( O
> O
=5 O
% O
Higher O
for O
All O
Grades O
or O
> O
=2 O
% O
Higher O
for O
Grades O
3/4 O
) O
with O
XALKORI O
than O
Chemotherapy O
in O
Study O
2Adverse O
reactions O
were O
graded O
using O
NCI O
CTCAE O
version O
4.0.Includes O
cases O
reported O
within O
the O
clustered O
terms O
: O
Adverse O
Reaction O
XALKORI O
( O
N=172 O
) O
Chemotherapy O
( O
Pemetrexed O
or O
Docetaxel O
) O
( O
N=171 O
) O
All O
Grades O
( O
% O
) O
Grade O
3-4 O
( O
% O
) O
All O
Grades O
( O
% O
) O
Grade O
3-4 O
( O
% O
) O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Dizziness B-OSE_Labeled_AE
[ O
note O
: O
Dizziness B-OSE_Labeled_AE
( O
Balance B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
Dizziness B-OSE_Labeled_AE
, O
Postural B-OSE_Labeled_AE
dizziness I-OSE_Labeled_AE
) O
. O
] O

22 O
1 O
8 O
0 O
Dysgeusia B-OSE_Labeled_AE
26 O
0 O
9 O
0 O
Syncope B-OSE_Labeled_AE
3 O
3 O
0 O
0 O
Eye B-NonOSE_AE
Disorders I-NonOSE_AE
Vision B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
[ O
note O
: O
Vision B-OSE_Labeled_AE
Disorder I-OSE_Labeled_AE
( O
Diplopia B-OSE_Labeled_AE
, O
Photophobia B-OSE_Labeled_AE
, O
Photopsia B-OSE_Labeled_AE
, O
Blurred B-OSE_Labeled_AE
vision I-OSE_Labeled_AE
, O
Reduced B-OSE_Labeled_AE
visual I-OSE_Labeled_AE
acuity I-OSE_Labeled_AE
, O
Visual B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
, O
Vitreous B-OSE_Labeled_AE
floaters I-OSE_Labeled_AE
) O
. O
] O

60 O
0 O
9 O
0 O
Cardiac B-NonOSE_AE
Disorders I-NonOSE_AE
Electrocardiogram B-OSE_Labeled_AE
QT I-OSE_Labeled_AE
prolonged I-OSE_Labeled_AE
5 O
3 O
0 O
0 O
Bradycardia B-OSE_Labeled_AE
[ O
note O
: O
Bradycardia B-OSE_Labeled_AE
( O
Bradycardia B-OSE_Labeled_AE
, O
Sinus B-OSE_Labeled_AE
bradycardia I-OSE_Labeled_AE
) O
. O
] O

5 O
0 O
0 O
0 O
Investigations B-NonOSE_AE
Decreased B-OSE_Labeled_AE
weight I-OSE_Labeled_AE
10 O
1 O
4 O
0 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Vomiting B-OSE_Labeled_AE
47 O
1 O
18 O
0 O
Nausea B-OSE_Labeled_AE
55 O
1 O
37 O
1 O
Diarrhea B-OSE_Labeled_AE
60 O
0 O
19 O
1 O
Constipation B-OSE_Labeled_AE
42 O
2 O
23 O
0 O
Dyspepsia B-OSE_Labeled_AE
8 O
0 O
3 O
0 O
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
[ O
note O
: O
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
Laryngitis B-OSE_Labeled_AE
, O
Nasopharyngitis B-OSE_Labeled_AE
, O
Pharyngitis B-OSE_Labeled_AE
, O
Rhinitis B-OSE_Labeled_AE
, O
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
) O
. O
] O

26 O
0 O
13 O
1 O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
Thoracic I-NonOSE_AE
and I-NonOSE_AE
Mediastinal I-NonOSE_AE
Disorders I-NonOSE_AE
Pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
[ O
note O
: O
Pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
( O
Pulmonary B-OSE_Labeled_AE
artery I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
, O
Pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
) O
. O
] O

6 O
5 O
2 O
2 O
General B-NonOSE_AE
Disorders I-NonOSE_AE
and I-NonOSE_AE
Administration I-NonOSE_AE
Site I-NonOSE_AE
Conditions I-NonOSE_AE
Edema B-OSE_Labeled_AE
[ O
note O
: O
Edema B-OSE_Labeled_AE
( O
Face B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
Generalized B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
Local B-OSE_Labeled_AE
swelling I-OSE_Labeled_AE
, O
Localized B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
Edema B-OSE_Labeled_AE
, O
Peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
Periorbital B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
) O
. O
] O

31 O
0 O
16 O
0 O
Additional O
adverse O
reactions O
occurring O
at O
an O
overall O
incidence O
between O
1 O
% O
and O
30 O
% O
in O
patients O
treated O
with O
XALKORI O
included O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
( O
27 O
% O
) O
, O
fatigue B-OSE_Labeled_AE
( O
27 O
% O
) O
, O
neuropathy B-OSE_Labeled_AE
( O
19 O
% O
; O
dysesthesia B-OSE_Labeled_AE
, O
gait B-OSE_Labeled_AE
disturbance I-OSE_Labeled_AE
, O
hypoesthesia B-OSE_Labeled_AE
, O
muscular B-OSE_Labeled_AE
weakness I-OSE_Labeled_AE
, O
neuralgia B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
, O
paresthesia B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
sensory I-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
, O
polyneuropathy B-OSE_Labeled_AE
, O
burning B-OSE_Labeled_AE
sensation I-OSE_Labeled_AE
in I-OSE_Labeled_AE
skin I-OSE_Labeled_AE
) O
, O
rash B-OSE_Labeled_AE
( O
9 O
% O
) O
, O
ILD B-OSE_Labeled_AE
( O
4 O
% O
; O
acute B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
distress I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
ILD B-OSE_Labeled_AE
, O
pneumonitis B-OSE_Labeled_AE
) O
, O
renal B-OSE_Labeled_AE
cyst I-OSE_Labeled_AE
( O
4 O
% O
) O
, O
esophagitis B-OSE_Labeled_AE
( O
2 O
% O
) O
, O
hepatic B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
( O
1 O
% O
) O
, O
and O
decreased B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
testosterone I-OSE_Labeled_AE
( O
1 O
% O
; O
hypogonadism B-OSE_Labeled_AE
) O
. O

Table O
6 O
. O

Laboratory O
Abnormalities O
with O
Grade O
3 O
or O
4 O
Incidence O
of O
> O
=4 O
% O
in O
XALKORI-Treated O
Patients O
in O
Study O
2 O
Laboratory O
Abnormality O
XALKORI O
Chemotherapy O
Any O
Grade O
( O
% O
) O
Grade O
3-4 O
( O
% O
) O
Any O
Grade O
( O
% O
) O
Grade O
3-4 O
( O
% O
) O
Additional O
laboratory B-NonOSE_AE
test I-NonOSE_AE
abnormality I-NonOSE_AE
in O
patients O
treated O
with O
XALKORI O
was O
an O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
( O
Any O
Grade O
: O
96 O
% O
; O
Grade O
3 O
: O
1 O
% O
; O
Grade O
4 O
: O
0 O
% O
) O
compared O
to O
the O
chemotherapy O
arm O
( O
Any O
Grade O
: O
72 O
% O
; O
Grade O
3 O
: O
0 O
% O
; O
Grade O
4 O
: O
0 O
% O
) O
. O

Hematology B-NonOSE_AE
Neutropenia B-OSE_Labeled_AE
49 O
12 O
28 O
12 O
Lymphopenia B-OSE_Labeled_AE
51 O
9 O
60 O
25 O
Chemistry B-NonOSE_AE
ALT B-OSE_Labeled_AE
elevation I-OSE_Labeled_AE
76 O
17 O
38 O
4 O
AST B-OSE_Labeled_AE
elevation I-OSE_Labeled_AE
61 O
9 O
33 O
0 O
Hypokalemia B-OSE_Labeled_AE
18 O
4 O
10 O
1 O
Hypophosphatemia B-OSE_Labeled_AE
28 O
5 O
25 O
6 O
ROS1-Positive O
Metastatic O
NSCLC O
- O
Study O
3 O
The O
safety O
profile O
of O
XALKORI O
from O
Study O
3 O
, O
which O
was O
evaluated O
in O
50 O
patients O
with O
ROS1-positive O
metastatic B-Not_AE_Candidate
NSCLC I-Not_AE_Candidate
, O
was O
generally O
consistent O
with O
the O
safety O
profile O
of O
XALKORI O
evaluated O
in O
patients O
with O
ALK B-Not_AE_Candidate
- I-Not_AE_Candidate
positive I-Not_AE_Candidate
metastatic B-Not_AE_Candidate
NSCLC I-Not_AE_Candidate
( O
n=1669 O
) O
. O

Vision B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
occurred O
in O
92 O
% O
of O
patients O
in O
Study O
3 O
; O
90 O
% O
were O
Grade O
1 O
and O
2 O
% O
were O
Grade O
2 O
. O

The O
median O
duration O
of O
exposure O
to O
XALKORI O
was O
34.4 O
months O
. O

Description O
of O
Selected O
Adverse O
Drug O
Reactions O
Vision O
disorders O
Vision B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
, O
most O
commonly O
visual B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
, O
photopsia B-OSE_Labeled_AE
, O
blurred B-OSE_Labeled_AE
vision I-OSE_Labeled_AE
, O
or O
vitreous B-OSE_Labeled_AE
floaters I-OSE_Labeled_AE
, O
occurred O
in O
1084 O
( O
63.1 O
% O
) O
of O
1719 O
patients O
. O

The O
majority O
( O
95 O
% O
) O
of O
these O
patients O
had O
Grade O
1 O
visual B-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

There O
were O
13 O
( O
0.8 O
% O
) O
patients O
with O
Grade O
3 O
and O
4 O
( O
0.2 O
% O
) O
patients O
with O
Grade O
4 O
visual B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
. O

Based O
on O
the O
Visual O
Symptom O
Assessment O
Questionnaire O
( O
VSAQ-ALK O
) O
, O
patients O
treated O
with O
XALKORI O
in O
Studies O
1 O
and O
2 O
reported O
a O
higher O
incidence O
of O
visual B-OSE_Labeled_AE
disturbances I-OSE_Labeled_AE
compared O
to O
patients O
treated O
with O
chemotherapy O
. O

The O
onset O
of O
vision B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
generally O
was O
within O
the O
first O
week O
of O
drug O
administration O
. O

The O
majority O
of O
patients O
on O
the O
XALKORI O
arms O
in O
Studies O
1 O
and O
2 O
( O
> O
50 O
% O
) O
reported O
visual B-OSE_Labeled_AE
disturbances I-OSE_Labeled_AE
which O
occurred O
at O
a O
frequency O
of O
4-7 O
days O
each O
week O
, O
lasted O
up O
to O
1 O
minute O
, O
and O
had O
mild O
or O
no O
impact O
( O
scores O
0 O
to O
3 O
out O
of O
a O
maximum O
score O
of O
10 O
) O
on O
daily O
activities O
as O
captured O
in O
the O
VSAQ-ALK O
questionnaire O
. O

Neuropathy O
Neuropathy B-OSE_Labeled_AE
, O
most O
commonly O
sensory O
in O
nature O
, O
occurred O
in O
435 O
( O
25 O
% O
) O
of O
1719 O
patients O
. O

Most O
events O
( O
95 O
% O
) O
were O
Grade O
1 O
or O
Grade O
2 O
in O
severity O
. O

Renal O
cysts O
Renal B-OSE_Labeled_AE
cysts I-OSE_Labeled_AE
were O
experienced O
by O
52 O
( O
3 O
% O
) O
of O
1719 O
patients O
. O

The O
majority O
of O
renal B-OSE_Labeled_AE
cysts I-OSE_Labeled_AE
in O
XALKORI-treated O
patients O
were O
complex O
. O

Local B-OSE_Labeled_AE
cystic I-OSE_Labeled_AE
invasion I-OSE_Labeled_AE
beyond I-OSE_Labeled_AE
the I-OSE_Labeled_AE
kidney I-OSE_Labeled_AE
occurred O
, O
in O
some O
cases O
with O
imaging O
characteristics O
suggestive O
of O
abscess B-NonOSE_AE
formation O
. O

However O
, O
across O
clinical O
trials O
no O
renal B-NonOSE_AE
abscesses I-NonOSE_AE
were O
confirmed O
by O
microbiology O
tests O
. O

Renal B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
The O
estimated O
glomerular B-OSE_Labeled_AE
filtration I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
( I-OSE_Labeled_AE
eGFR I-OSE_Labeled_AE
) I-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
from O
a O
baseline O
median O
of O
96.42 O
mL/min/1.73 O
m O
2 O
( O
n=1681 O
) O
to O
a O
median O
of O
80.23 O
mL/min/1.73 O
m O
2 O
at O
2 O
weeks O
( O
n=1499 O
) O
in O
patients O
with O
ALK B-Not_AE_Candidate
- I-Not_AE_Candidate
positive I-Not_AE_Candidate
advanced O
NSCLC B-Not_AE_Candidate
who O
received O
XALKORI O
in O
clinical O
trials O
. O

No O
clinically O
relevant O
changes O
occurred O
in O
median O
eGFR O
from O
12 O
to O
104 O
weeks O
of O
treatment O
. O

Median O
eGFR B-NonOSE_AE
slightly I-NonOSE_AE
increased I-NonOSE_AE
( O
83.02 O
mL/min/1.73 O
m O
2 O
) O
4 O
weeks O
after O
the O
last O
dose O
of O
XALKORI O
. O

Overall O
, O
76 O
% O
of O
patients O
had O
a O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
eGFR I-OSE_Labeled_AE
to O
< O
90 O
mL/min/1.73 O
m O
2 O
, O
38 O
% O
had O
a O
decrease B-OSE_Labeled_AE
to O
eGFR I-OSE_Labeled_AE
to O
< O
60 O
mL/min/1.73 O
m O
2 O
, O
and O
3.6 O
% O
had O
a O
decrease B-OSE_Labeled_AE
to O
eGFR I-OSE_Labeled_AE
to O
< O
30 O
mL/min/1.73 O
m O
2 O
. O

